Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...
Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...
CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...
News-Medical.Net on MSN
Recent advances in CAR-NK cell therapy could revolutionze cancer treatment
Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...
A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...
Allogeneic CD19 chimeric antigen receptor-natural killer (CAR-NK) cell therapy showed promise in patients with relapsed or refractory systemic lupus erythematosus (SLE), with sustained efficacy. The ...
GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...
GT Biopharma targets a portion of the estimated $362 billion global solid tumor marketPreliminary, unaudited cash balance of approximately $7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results